ID   BRDT_HUMAN              Reviewed;         947 AA.
AC   Q58F21; A6NF68; B7Z811; B7Z890; B7ZAX7; D3DT32; O14789; Q05DQ4; Q6P5T1;
AC   Q7Z4A6; Q8IWI6;
DT   30-MAY-2006, integrated into UniProtKB/Swiss-Prot.
DT   14-APR-2009, sequence version 4.
DT   12-OCT-2022, entry version 149.
DE   RecName: Full=Bromodomain testis-specific protein;
DE   AltName: Full=Cancer/testis antigen 9;
DE            Short=CT9;
DE   AltName: Full=RING3-like protein;
GN   Name=BRDT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY, AND
RP   VARIANTS LYS-62 AND LEU-696.
RX   PubMed=9367677; DOI=10.1006/geno.1997.5000;
RA   Jones M.H., Numata M., Shimane M.;
RT   "Identification and characterization of BRDT: a testis-specific gene
RT   related to the bromodomain genes RING3 and Drosophila fsh.";
RL   Genomics 45:529-534(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, ALTERNATIVE SPLICING,
RP   TISSUE SPECIFICITY, AND VARIANTS LYS-62 AND LEU-696.
RC   TISSUE=Testis;
RX   PubMed=15647849;
RA   Zheng Y., Yuan W., Zhou Z., Xu M., Sha J.-H.;
RT   "Molecular cloning and expression of a novel alternative splice variant of
RT   BRDT gene.";
RL   Int. J. Mol. Med. 15:315-321(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANTS
RP   LYS-62 AND LEU-696.
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANTS LYS-62 AND
RP   LEU-696.
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-462 (ISOFORM 1), AND VARIANTS
RP   LYS-62; ASN-238 AND LYS-410.
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, AND IDENTIFICATION AS A CANCER/TESTIS ANTIGEN.
RX   PubMed=10704737; DOI=10.1016/s0304-3835(99)00385-7;
RA   Scanlan M.J., Altorki N.K., Gure A.O., Williamson B., Jungbluth A.,
RA   Chen Y.-T., Old L.J.;
RT   "Expression of cancer-testis antigens in lung cancer: definition of
RT   bromodomain testis-specific gene (BRDT) as a new CT gene, CT9.";
RL   Cancer Lett. 150:155-164(2000).
RN   [8]
RP   VARIANTS [LARGE SCALE ANALYSIS] PHE-2; GLN-6; VAL-89; ASN-238; TYR-288;
RP   LYS-357; LYS-410 AND ALA-542.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20538714; DOI=10.1530/rep-10-0139;
RA   Steilmann C., Cavalcanti M.C., Bartkuhn M., Pons-Kuhnemann J.,
RA   Schuppe H.C., Weidner W., Steger K., Paradowska A.;
RT   "The interaction of modified histones with the bromodomain testis-specific
RT   (BRDT) gene and its mRNA level in sperm of fertile donors and subfertile
RT   men.";
RL   Reproduction 140:435-443(2010).
RN   [10]
RP   SUBCELLULAR LOCATION, AND MOTIF NUCLEAR LOCALIZATION SIGNAL.
RX   PubMed=22971749; DOI=10.1248/bpb.b12-00527;
RA   Fukazawa H., Masumi A.;
RT   "The conserved 12-amino acid stretch in the inter-bromodomain region of BET
RT   family proteins functions as a nuclear localization signal.";
RL   Biol. Pharm. Bull. 35:2064-2068(2012).
RN   [11] {ECO:0007744|PDB:2RFJ}
RP   X-RAY CRYSTALLOGRAPHY (2.05 ANGSTROMS) OF 21-137, FUNCTION, SUBUNIT, AND
RP   DOMAIN.
RX   PubMed=22464331; DOI=10.1016/j.cell.2012.02.013;
RA   Filippakopoulos P., Picaud S., Mangos M., Keates T., Lambert J.P.,
RA   Barsyte-Lovejoy D., Felletar I., Volkmer R., Muller S., Pawson T.,
RA   Gingras A.C., Arrowsmith C.H., Knapp S.;
RT   "Histone recognition and large-scale structural analysis of the human
RT   bromodomain family.";
RL   Cell 149:214-231(2012).
RN   [12] {ECO:0007744|PDB:4FLP}
RP   X-RAY CRYSTALLOGRAPHY (2.23 ANGSTROMS) OF 21-137 IN COMPLEX WITH JQ1,
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=22901802; DOI=10.1016/j.cell.2012.06.045;
RA   Matzuk M.M., McKeown M.R., Filippakopoulos P., Li Q., Ma L., Agno J.E.,
RA   Lemieux M.E., Picaud S., Yu R.N., Qi J., Knapp S., Bradner J.E.;
RT   "Small-molecule inhibition of BRDT for male contraception.";
RL   Cell 150:673-684(2012).
RN   [13]
RP   VARIANT SPGF21 ASP-928, AND CHARACTERIZATION OF VARIANT SPGF21 ASP-928.
RX   PubMed=28199965; DOI=10.18632/oncotarget.15251;
RA   Li L., Sha Y., Wang X., Li P., Wang J., Kee K., Wang B.;
RT   "Whole-exome sequencing identified a homozygous BRDT mutation in a patient
RT   with acephalic spermatozoa.";
RL   Oncotarget 8:19914-19922(2017).
CC   -!- FUNCTION: Testis-specific chromatin protein that specifically binds
CC       histone H4 acetylated at 'Lys-5' and 'Lys-8' (H4K5ac and H4K8ac,
CC       respectively) and plays a key role in spermatogenesis (PubMed:22464331,
CC       PubMed:22901802). Required in late pachytene spermatocytes: plays a
CC       role in meiotic and post-meiotic cells by binding to acetylated
CC       histones at the promoter of specific meiotic and post-meiotic genes,
CC       facilitating their activation at the appropriate time
CC       (PubMed:22901802). In the post-meiotic phase of spermatogenesis, binds
CC       to hyperacetylated histones and participates in their general removal
CC       from DNA (PubMed:22901802). Also recognizes and binds a subset of
CC       butyrylated histones: able to bind histone H4 butyrylated at 'Lys-8'
CC       (H4K8ac), while it is not able to bind H4 butyrylated at 'Lys-5'
CC       (H4K5ac) (By similarity). Also acts as a component of the splicing
CC       machinery in pachytene spermatocytes and round spermatids and
CC       participates in 3'-UTR truncation of specific mRNAs in post-meiotic
CC       spermatids (By similarity). Required for chromocenter organization, a
CC       structure comprised of peri-centromeric heterochromatin.
CC       {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:15647849,
CC       ECO:0000269|PubMed:22464331, ECO:0000269|PubMed:22901802,
CC       ECO:0000269|PubMed:9367677}.
CC   -!- SUBUNIT: Interacts with mRNA splicing machinery proteins SRSF2, DDX5,
CC       HNRNPK and TARDBP. Interacts with the acetylated N-terminus of histone
CC       H1, H2, H3 and H4. Interacts with P-TEFb components CDK9 and
CC       CCNT1/cyclin-T1. Interacts with SMARCE1 (By similarity). Interacts with
CC       the acetylated N-terminus of histone H1.4, H2A, H2B, H3 and H4.
CC       {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331,
CC       ECO:0000269|PubMed:22901802}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:20538714,
CC       ECO:0000269|PubMed:22901802, ECO:0000269|PubMed:22971749}.
CC       Note=Detected on chromatin. {ECO:0000250|UniProtKB:Q91Y44}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q58F21-1; Sequence=Displayed;
CC       Name=2; Synonyms=BRDT-NY;
CC         IsoId=Q58F21-2; Sequence=VSP_019118;
CC       Name=3;
CC         IsoId=Q58F21-3; Sequence=VSP_044511;
CC       Name=4;
CC         IsoId=Q58F21-4; Sequence=VSP_044510;
CC       Name=5;
CC         IsoId=Q58F21-5; Sequence=VSP_044509;
CC   -!- TISSUE SPECIFICITY: Testis-specific. A 3-fold higher expression is seen
CC       in adult testis than in embryo testis. Expression seems to be
CC       correlated with histone H4 hyperacetylation during the haploid phase of
CC       spermatogenesis (spermiogenesis). No expression, or very low expression
CC       is seen in patients' testes with abnormal spermatogenesis. Expressed in
CC       cancers such as non-small cell lung cancer and squamous cell carcinomas
CC       of the head and neck as well as of esophagus, but not in melanoma or in
CC       cancers of the colon, breast, kidney and bladder.
CC       {ECO:0000269|PubMed:10704737, ECO:0000269|PubMed:15647849,
CC       ECO:0000269|PubMed:9367677}.
CC   -!- DEVELOPMENTAL STAGE: Expressed in embryo testis.
CC   -!- DOMAIN: Bromo domains mediate interaction with histones that have
CC       acetylated lysine residues at specific positions (PubMed:22464331).
CC       Bromo domain 1 mediates binding with histone H4 acetylated at 'Lys-5'
CC       and 'Lys-8' (H4K5ac and H4K8ac, respectively) (PubMed:22901802). The
CC       bromo domains also recognize and bind a subset of butyrylated histones:
CC       able to bind histone H4 butyrylated at 'Lys-8' (H4K8ac), while it is
CC       not able to bind H4 butyrylated at 'Lys-5' (H4K5ac) (By similarity).
CC       {ECO:0000250|UniProtKB:Q91Y44, ECO:0000269|PubMed:22464331,
CC       ECO:0000269|PubMed:22901802}.
CC   -!- DISEASE: Spermatogenic failure 21 (SPGF21) [MIM:617644]: An infertility
CC       disorder caused by spermatogenesis defects and characterized by
CC       acephalic spermatozoa in the semen of affected individuals. SPGF21
CC       inheritance is autosomal recessive. {ECO:0000269|PubMed:28199965}.
CC       Note=The disease is caused by variants affecting the gene represented
CC       in this entry.
CC   -!- MISCELLANEOUS: BRDT is a promising target for male contraception.
CC       Inhibition by thienodiazepine inhibitor (+)-JQ1 that binds Asn-109,
CC       prevents recognition of acetylated histone H4, causing a complete and
CC       reversible contraceptive effect in male mice (PubMed:22901802).
CC       {ECO:0000305|PubMed:22901802}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH05281.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH47900.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC       Sequence=AAH62700.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Potential poly-A sequence.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Asking life to be patient
CC       - Issue 144 of November 2012;
CC       URL="https://web.expasy.org/spotlight/back_issues/144";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF019085; AAB87862.1; -; mRNA.
DR   EMBL; AY338951; AAQ16198.1; -; mRNA.
DR   EMBL; AK303008; BAH13876.1; -; mRNA.
DR   EMBL; AK302758; BAH13797.1; -; mRNA.
DR   EMBL; AK316442; BAH14813.1; -; mRNA.
DR   EMBL; AC114486; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471097; EAW73106.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73107.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73108.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73110.1; -; Genomic_DNA.
DR   EMBL; CH471097; EAW73111.1; -; Genomic_DNA.
DR   EMBL; BC005281; AAH05281.1; ALT_SEQ; mRNA.
DR   EMBL; BC017582; AAH17582.1; -; mRNA.
DR   EMBL; BC047900; AAH47900.1; ALT_SEQ; mRNA.
DR   EMBL; BC062700; AAH62700.1; ALT_SEQ; mRNA.
DR   CCDS; CCDS55615.1; -. [Q58F21-4]
DR   CCDS; CCDS55616.1; -. [Q58F21-5]
DR   CCDS; CCDS72820.1; -. [Q58F21-3]
DR   CCDS; CCDS735.1; -. [Q58F21-1]
DR   RefSeq; NP_001229734.2; NM_001242805.2. [Q58F21-1]
DR   RefSeq; NP_001229735.2; NM_001242806.2. [Q58F21-3]
DR   RefSeq; NP_001229736.2; NM_001242807.2. [Q58F21-4]
DR   RefSeq; NP_001229737.2; NM_001242808.2. [Q58F21-4]
DR   RefSeq; NP_001229739.2; NM_001242810.2. [Q58F21-5]
DR   RefSeq; NP_001717.3; NM_001726.4. [Q58F21-1]
DR   RefSeq; NP_997072.2; NM_207189.3. [Q58F21-1]
DR   RefSeq; XP_006710916.1; XM_006710853.3. [Q58F21-1]
DR   RefSeq; XP_006710917.1; XM_006710854.3. [Q58F21-1]
DR   RefSeq; XP_006710918.1; XM_006710855.3. [Q58F21-1]
DR   RefSeq; XP_006710919.1; XM_006710856.3. [Q58F21-1]
DR   RefSeq; XP_006710920.1; XM_006710857.3. [Q58F21-1]
DR   RefSeq; XP_011540334.1; XM_011542032.2. [Q58F21-1]
DR   RefSeq; XP_011540335.1; XM_011542033.2. [Q58F21-1]
DR   RefSeq; XP_011540336.1; XM_011542034.2. [Q58F21-1]
DR   RefSeq; XP_011540337.1; XM_011542035.2. [Q58F21-1]
DR   RefSeq; XP_011540338.1; XM_011542036.2. [Q58F21-1]
DR   PDB; 2RFJ; X-ray; 2.05 A; A/B/C=21-137.
DR   PDB; 4FLP; X-ray; 2.23 A; A/B=21-137.
DR   PDB; 4KCX; X-ray; 2.00 A; A/B=21-137.
DR   PDB; 5VBQ; X-ray; 1.65 A; A/B=29-137.
DR   PDB; 5VBR; X-ray; 1.90 A; A/B=29-137.
DR   PDB; 7BJY; X-ray; 2.22 A; A/B=29-137.
DR   PDB; 7L73; X-ray; 1.46 A; A=29-137.
DR   PDB; 7L99; X-ray; 1.90 A; A/B/C/D=269-380.
DR   PDB; 7L9A; X-ray; 2.27 A; A/B=269-380.
DR   PDB; 7LEJ; X-ray; 1.73 A; A=266-378.
DR   PDB; 7LEK; X-ray; 2.75 A; A/B/C/D=266-378.
DR   PDB; 7LEL; X-ray; 2.15 A; A/B/C/D=266-378.
DR   PDB; 7LEM; X-ray; 1.89 A; A/B=29-137.
DR   PDBsum; 2RFJ; -.
DR   PDBsum; 4FLP; -.
DR   PDBsum; 4KCX; -.
DR   PDBsum; 5VBQ; -.
DR   PDBsum; 5VBR; -.
DR   PDBsum; 7BJY; -.
DR   PDBsum; 7L73; -.
DR   PDBsum; 7L99; -.
DR   PDBsum; 7L9A; -.
DR   PDBsum; 7LEJ; -.
DR   PDBsum; 7LEK; -.
DR   PDBsum; 7LEL; -.
DR   PDBsum; 7LEM; -.
DR   AlphaFoldDB; Q58F21; -.
DR   SASBDB; Q58F21; -.
DR   SMR; Q58F21; -.
DR   BioGRID; 107143; 76.
DR   IntAct; Q58F21; 2.
DR   STRING; 9606.ENSP00000387822; -.
DR   BindingDB; Q58F21; -.
DR   ChEMBL; CHEMBL1795185; -.
DR   GuidetoPHARMACOLOGY; 2729; -.
DR   iPTMnet; Q58F21; -.
DR   PhosphoSitePlus; Q58F21; -.
DR   BioMuta; BRDT; -.
DR   DMDM; 226694198; -.
DR   EPD; Q58F21; -.
DR   jPOST; Q58F21; -.
DR   MassIVE; Q58F21; -.
DR   MaxQB; Q58F21; -.
DR   PaxDb; Q58F21; -.
DR   PeptideAtlas; Q58F21; -.
DR   PRIDE; Q58F21; -.
DR   ProteomicsDB; 1029; -.
DR   ProteomicsDB; 62618; -. [Q58F21-1]
DR   ProteomicsDB; 62619; -. [Q58F21-2]
DR   Antibodypedia; 3212; 134 antibodies from 22 providers.
DR   DNASU; 676; -.
DR   Ensembl; ENST00000362005.7; ENSP00000354568.3; ENSG00000137948.19. [Q58F21-1]
DR   Ensembl; ENST00000370389.6; ENSP00000359416.2; ENSG00000137948.19. [Q58F21-5]
DR   Ensembl; ENST00000394530.7; ENSP00000378038.3; ENSG00000137948.19. [Q58F21-4]
DR   Ensembl; ENST00000399546.7; ENSP00000387822.3; ENSG00000137948.19. [Q58F21-1]
DR   Ensembl; ENST00000402388.1; ENSP00000384051.1; ENSG00000137948.19. [Q58F21-1]
DR   GeneID; 676; -.
DR   KEGG; hsa:676; -.
DR   MANE-Select; ENST00000399546.7; ENSP00000387822.3; NM_207189.4; NP_997072.2.
DR   UCSC; uc001dol.5; human. [Q58F21-1]
DR   CTD; 676; -.
DR   DisGeNET; 676; -.
DR   GeneCards; BRDT; -.
DR   HGNC; HGNC:1105; BRDT.
DR   HPA; ENSG00000137948; Tissue enriched (testis).
DR   MalaCards; BRDT; -.
DR   MIM; 602144; gene.
DR   MIM; 617644; phenotype.
DR   neXtProt; NX_Q58F21; -.
DR   OpenTargets; ENSG00000137948; -.
DR   PharmGKB; PA25418; -.
DR   VEuPathDB; HostDB:ENSG00000137948; -.
DR   eggNOG; KOG1474; Eukaryota.
DR   GeneTree; ENSGT00940000154549; -.
DR   HOGENOM; CLU_001499_0_0_1; -.
DR   InParanoid; Q58F21; -.
DR   OMA; FMQKIAQ; -.
DR   OrthoDB; 619848at2759; -.
DR   PhylomeDB; Q58F21; -.
DR   TreeFam; TF317345; -.
DR   PathwayCommons; Q58F21; -.
DR   SignaLink; Q58F21; -.
DR   SIGNOR; Q58F21; -.
DR   BioGRID-ORCS; 676; 14 hits in 1086 CRISPR screens.
DR   ChiTaRS; BRDT; human.
DR   EvolutionaryTrace; Q58F21; -.
DR   GeneWiki; BRDT; -.
DR   GenomeRNAi; 676; -.
DR   Pharos; Q58F21; Tchem.
DR   PRO; PR:Q58F21; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q58F21; protein.
DR   Bgee; ENSG00000137948; Expressed in left testis and 95 other tissues.
DR   ExpressionAtlas; Q58F21; baseline and differential.
DR   Genevisible; Q58F21; HS.
DR   GO; GO:0000785; C:chromatin; IBA:GO_Central.
DR   GO; GO:0005634; C:nucleus; ISS:UniProtKB.
DR   GO; GO:0042393; F:histone binding; IDA:UniProtKB.
DR   GO; GO:0140566; F:histone reader activity; ISS:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; ISS:UniProtKB.
DR   GO; GO:0003713; F:transcription coactivator activity; TAS:ProtInc.
DR   GO; GO:0006338; P:chromatin remodeling; ISS:UniProtKB.
DR   GO; GO:0007141; P:male meiosis I; ISS:UniProtKB.
DR   GO; GO:0007140; P:male meiotic nuclear division; ISS:UniProtKB.
DR   GO; GO:0006397; P:mRNA processing; IEA:UniProtKB-KW.
DR   GO; GO:0051039; P:positive regulation of transcription involved in meiotic cell cycle; ISS:UniProtKB.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:UniProtKB.
DR   GO; GO:0043484; P:regulation of RNA splicing; ISS:UniProtKB.
DR   GO; GO:0008380; P:RNA splicing; IEA:UniProtKB-KW.
DR   GO; GO:0035093; P:spermatogenesis, exchange of chromosomal proteins; ISS:UniProtKB.
DR   CDD; cd05497; Bromo_Brdt_I_like; 1.
DR   CDD; cd05498; Bromo_Brdt_II_like; 1.
DR   Gene3D; 1.20.1270.220; -; 1.
DR   Gene3D; 1.20.920.10; -; 2.
DR   InterPro; IPR031354; BRD4_CDT.
DR   InterPro; IPR043508; Bromo_Brdt_I.
DR   InterPro; IPR043509; Bromo_Brdt_II.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR027353; NET_dom.
DR   InterPro; IPR038336; NET_sf.
DR   Pfam; PF17035; BET; 1.
DR   Pfam; PF17105; BRD4_CDT; 1.
DR   Pfam; PF00439; Bromodomain; 2.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00297; BROMO; 2.
DR   SUPFAM; SSF47370; SSF47370; 2.
DR   PROSITE; PS00633; BROMODOMAIN_1; 2.
DR   PROSITE; PS50014; BROMODOMAIN_2; 2.
DR   PROSITE; PS51525; NET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activator; Alternative splicing; Bromodomain;
KW   Chromatin regulator; Coiled coil; Differentiation; Disease variant;
KW   Meiosis; mRNA processing; mRNA splicing; Nucleus; Phosphoprotein;
KW   Reference proteome; Repeat; Spermatogenesis; Transcription;
KW   Transcription regulation.
FT   CHAIN           1..947
FT                   /note="Bromodomain testis-specific protein"
FT                   /id="PRO_0000239225"
FT   DOMAIN          44..116
FT                   /note="Bromo 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          287..359
FT                   /note="Bromo 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   DOMAIN          500..582
FT                   /note="NET"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00857"
FT   REGION          202..228
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          395..420
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          444..511
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          610..698
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          882..924
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          417..470
FT                   /evidence="ECO:0000255"
FT   COILED          591..621
FT                   /evidence="ECO:0000255"
FT   MOTIF           209..220
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:22971749"
FT   COMPBIAS        395..409
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        459..483
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        495..511
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        626..667
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        668..695
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        884..924
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         109
FT                   /ligand="JQ1"
FT                   /ligand_id="ChEBI:CHEBI:137113"
FT                   /ligand_note="inhibitor"
FT                   /evidence="ECO:0000269|PubMed:22901802,
FT                   ECO:0007744|PDB:4FLP"
FT   SITE            109
FT                   /note="Histone H4K5ac binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q91Y44"
FT   SITE            114
FT                   /note="Histone H4K5ac binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q91Y44"
FT   MOD_RES         187
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q91Y44"
FT   VAR_SEQ         1..73
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_044509"
FT   VAR_SEQ         1
FT                   /note="M -> MTCTCRQDSKQLRM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15647849"
FT                   /id="VSP_019118"
FT   VAR_SEQ         65..110
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044510"
FT   VAR_SEQ         148
FT                   /note="K -> KGKAG (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044511"
FT   VARIANT         2
FT                   /note="S -> F (in dbSNP:rs55806733)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041924"
FT   VARIANT         6
FT                   /note="R -> Q (in dbSNP:rs56273490)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041925"
FT   VARIANT         62
FT                   /note="Q -> K (in dbSNP:rs10783071)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:15647849,
FT                   ECO:0000269|PubMed:9367677, ECO:0000269|Ref.5"
FT                   /id="VAR_026584"
FT   VARIANT         89
FT                   /note="A -> V (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs781375003)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041926"
FT   VARIANT         238
FT                   /note="K -> N (in dbSNP:rs1156281)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_026585"
FT   VARIANT         288
FT                   /note="H -> Y (in a lung neuroendocrine carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041927"
FT   VARIANT         336
FT                   /note="K -> T (in dbSNP:rs1064567)"
FT                   /id="VAR_047327"
FT   VARIANT         357
FT                   /note="E -> K (in dbSNP:rs34674879)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041928"
FT   VARIANT         410
FT                   /note="N -> K (in dbSNP:rs3088232)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:17344846"
FT                   /id="VAR_026586"
FT   VARIANT         542
FT                   /note="P -> A (in dbSNP:rs55912588)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041929"
FT   VARIANT         605
FT                   /note="R -> Q (in dbSNP:rs35327986)"
FT                   /id="VAR_047328"
FT   VARIANT         696
FT                   /note="P -> L (in dbSNP:rs10747493)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15647849, ECO:0000269|PubMed:9367677,
FT                   ECO:0000269|Ref.5"
FT                   /id="VAR_047329"
FT   VARIANT         928
FT                   /note="G -> D (in SPGF21; no effect on protein expression;
FT                   unknown pathological significance; dbSNP:rs754258809)"
FT                   /evidence="ECO:0000269|PubMed:28199965"
FT                   /id="VAR_079306"
FT   CONFLICT        42
FT                   /note="D -> N (in Ref. 3; BAH13876)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        73
FT                   /note="P -> S (in Ref. 6; AAH05281)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="K -> I (in Ref. 6; AAH62700)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        265
FT                   /note="K -> E (in Ref. 1; AAB87862)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        336
FT                   /note="K -> S (in Ref. 1; AAB87862)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        462
FT                   /note="E -> K (in Ref. 6; AAH17582)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        477
FT                   /note="Q -> R (in Ref. 3; BAH13876)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        552
FT                   /note="I -> M (in Ref. 2; AAQ16198)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        686
FT                   /note="N -> H (in Ref. 1; AAB87862)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        893
FT                   /note="Q -> P (in Ref. 1; AAB87862)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        915
FT                   /note="Q -> P (in Ref. 1; AAB87862)"
FT                   /evidence="ECO:0000305"
FT   HELIX           29..37
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           39..45
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           50..52
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   STRAND          53..55
FT                   /evidence="ECO:0007829|PDB:2RFJ"
FT   TURN            58..62
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           66..69
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           76..84
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           91..108
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           114..131
FT                   /evidence="ECO:0007829|PDB:7L73"
FT   HELIX           266..284
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           286..288
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           289..292
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   STRAND          296..298
FT                   /evidence="ECO:0007829|PDB:7L99"
FT   HELIX           301..304
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           309..312
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           319..327
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           334..351
FT                   /evidence="ECO:0007829|PDB:7LEJ"
FT   HELIX           357..373
FT                   /evidence="ECO:0007829|PDB:7LEJ"
SQ   SEQUENCE   947 AA;  107954 MW;  09C0FD8690E217BB CRC64;
     MSLPSRQTAI IVNPPPPEYI NTKKNGRLTN QLQYLQKVVL KDLWKHSFSW PFQRPVDAVK
     LQLPDYYTII KNPMDLNTIK KRLENKYYAK ASECIEDFNT MFSNCYLYNK PGDDIVLMAQ
     ALEKLFMQKL SQMPQEEQVV GVKERIKKGT QQNIAVSSAK EKSSPSATEK VFKQQEIPSV
     FPKTSISPLN VVQGASVNSS SQTAAQVTKG VKRKADTTTP ATSAVKASSE FSPTFTEKSV
     ALPPIKENMP KNVLPDSQQQ YNVVKTVKVT EQLRHCSEIL KEMLAKKHFS YAWPFYNPVD
     VNALGLHNYY DVVKNPMDLG TIKEKMDNQE YKDAYKFAAD VRLMFMNCYK YNPPDHEVVT
     MARMLQDVFE THFSKIPIEP VESMPLCYIK TDITETTGRE NTNEASSEGN SSDDSEDERV
     KRLAKLQEQL KAVHQQLQVL SQVPFRKLNK KKEKSKKEKK KEKVNNSNEN PRKMCEQMRL
     KEKSKRNQPK KRKQQFIGLK SEDEDNAKPM NYDEKRQLSL NINKLPGDKL GRVVHIIQSR
     EPSLSNSNPD EIEIDFETLK ASTLRELEKY VSACLRKRPL KPPAKKIMMS KEELHSQKKQ
     ELEKRLLDVN NQLNSRKRQT KSDKTQPSKA VENVSRLSES SSSSSSSSES ESSSSDLSSS
     DSSDSESEMF PKFTEVKPND SPSKENVKKM KNECIPPEGR TGVTQIGYCV QDTTSANTTL
     VHQTTPSHVM PPNHHQLAFN YQELEHLQTV KNISPLQILP PSGDSEQLSN GITVMHPSGD
     SDTTMLESEC QAPVQKDIKI KNADSWKSLG KPVKPSGVMK SSDELFNQFR KAAIEKEVKA
     RTQELIRKHL EQNTKELKAS QENQRDLGNG LTVESFSNKI QNKCSGEEQK EHQQSSEAQD
     KSKLWLLKDR DLARQKEQER RRREAMVGTI DMTLQSDIMT MFENNFD
//
